04.04.2017 • Topics

We Actively Face the Challenges

Peter Overlack, Co-CEO, Overlack Group
Peter Overlack, Co-CEO, Overlack Group

“It has always been a tradition at Overlack Group to actively deal with ongoing developments, gather information and if necessary react. We began analyzing our processes very early on and have been exploiting the advantages of digitalization. With an internal team, supported by external expertise, we defined areas that we can make more efficient through digitalization, for example storage and logistics, procurement and distribution. However, we also realize that internal processes such as in-company communication, HR and administration could be more efficient as well. Here we see great potential for making our company more agile and resilient.

We also take things one step further and have asked ourselves what the business model of a distributor could be like in the future. Here again, we actively face the challenges and analyze the possibilities of disruptive changes to the chemical distribution market, for example market or industry platforms. That’s where we see the biggest challenges. At the same time it is also a big chance to get closer to the customer and to offer more effective service.

In addition to all the developments in the area of digitalization, as always the important thing is the basics that make our company competitive, such as good Europe-wide coverage, a full-line portfolio with a focus on specialty chemicals and good customer-oriented services.”

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read